(Q34091814)

English

Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

31 July 2017

Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy (English)

1 reference

Europe PubMed Central

31 July 2017

breast carcinoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Kumamoto H

1

1 reference

Europe PubMed Central

31 July 2017

Sasano H

2

1 reference

Europe PubMed Central

31 July 2017

Taniguchi T

3

1 reference

Europe PubMed Central

31 July 2017

Suzuki T

4

1 reference

Europe PubMed Central

31 July 2017

Moriya T

5

1 reference

Europe PubMed Central

31 July 2017

Ichinohasama R

6

1 reference

Europe PubMed Central

31 July 2017

publication date

1 August 2001

1 reference

Europe PubMed Central

31 July 2017

Pathology International

1 reference

Europe PubMed Central

31 July 2017

51

1 reference

Europe PubMed Central

31 July 2017

8

1 reference

Europe PubMed Central

31 July 2017

579-584

1 reference

Europe PubMed Central

31 July 2017

Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1827.2001.01255.X

21 January 2018

The biology of erbB-2/neu/HER-2 and its role in cancer

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1827.2001.01255.X

21 January 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1827.2001.01255.X

21 January 2018

Humanization of an anti-p185HER2 antibody for human cancer therapy

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1827.2001.01255.X

21 January 2018

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1827.2001.01255.X

21 January 2018

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1827.2001.01255.X

21 January 2018

Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1827.2001.01255.X

21 January 2018

Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1827.2001.01255.X

21 January 2018

Subtracted, unique-sequence, in situ hybridization: experimental and diagnostic applications

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1827.2001.01255.X

21 January 2018

Identifiers

10.1046/J.1440-1827.2001.01255.X

1 reference

Europe PubMed Central

31 July 2017

1 reference

Europe PubMed Central

31 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34091814&oldid=1561189793"